Innopharma Technology, based in Dublin and Glatt (India) Systems Pvt. Ltd. have entered a strategic collaboration aimed at reducing product manufacturing costs and increasing compliance and product quality for the pharmaceutical, MedTech and food industries.
 
The partnership offers Innopharma’s Process Analytical Technology (PAT) tools and support services to customers in India alongside Glatt’s pharmaceutical process equipment. Innopharma works with many R&D groups as well as GMP certified U.S. FDA approved manufacturing facilities of leading pharmaceutical companies in India.
 
With many pharmaceutical processing companies adopting a Quality by Design (QbD) approach to product development, these tools are used to capture critical real-time data during all stages of a product life cycle, from product development through to scale up and commercial manufacture.
 
“With this agreement, we have further expanded our strategic alliances for PAT systems,” said Ian Jones, chief executive officer of Innopharma Labs Ltd. “Signing this agreement with Glatt further validates the contribution PAT systems can make to pharmaceutical processing. We are very much looking forward to working with Glatt over the coming years and integrating further our Eyecon technology with Glatt’s fluid bed systems.”
 
“We are very pleased to sign this collaboration agreement with Innopharma,” said Rajiv Bhide, managing director, Glatt. “Incorporating the option for Innopharma Technology’s PAT solutions into our fluid bed and continuous process equipment will allow customers in India to greatly increase process knowledge and understanding and offer them the potential to reduce manufacturing costs and increase compliance and product quality.”